Brief: Igc Pharma Announces Additional Data Supporting Igc-Ad1 As An Alzheimer's Treatment
18/09/2024 14:04
Sept 18 (Reuters) - IGC Pharma Inc IGC.A :
* IGC PHARMA ANNOUNCES ADDITIONAL DATA SUPPORTING IGC-AD1 AS
AN
ALZHEIMER'S TREATMENT
* IGC PHARMA: IGC-AD1 DEMONSTRATES POTENTIAL TO MODIFY TAU
AND
IMPROVE SPATIAL MEMORY
* IGC PHARMA:DATA SUPPORTS INITIATION OF CLINICAL TRIALS
INVESTIGATING IGC-AD1 AS A TREATMENT FOR ALZHEIMER'S DISEASE
Source text for Eikon: ID:nBwD5zz7a
Further company coverage: IGC.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on IGC Pharma
See all newsFocus: Companies with cannabis-based drugs eye IPOs, private funding boost after US reclassification
Cannabis stocks climb after Trump signs order to ease curbs on marijuana (updated)
Cannabis stocks rise ahead of potential Trump order to ease marijuana restrictions
Brief: IGC Pharma's Unit Enters Sale Of Assets Agreement For $2.7 Million - SEC Filing
Brief: IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment